by LuminOneBook an introductory call ↗New application inquiry
A separate application journey could route a customer’s new intended use to specialists, keeping existing product evidence distinct from unverified suitability.
ARIA for life sciences reagent suppliers
Connect application evidence with the scientist’s question.
Commercial workflows for reagent suppliers across research, manufacturing and diagnostics. Connect scientific relevance, approved evidence, engagement and account development with intended-use boundaries intact.
Possible starting points
- Application relevance
- Scientific engagement
- Evaluation follow-up
From application question to informed follow-up
A fictional IHC/FFPE inquiry connects application evidence, specialist review and possible evaluation with commercial follow-up, without presuming fit or purchase.
Not a fixed product package.
Pathology research scientist · illustrative request
“Does this antibody work for IHC on FFPE sections? Your datasheet only shows western blot.”
Commercial perspective: Antibody commercial team.
ARIA PREPARES
Clarify application fit
An inquiry brief captures IHC on FFPE tissue and distinguishes the requested application from the supplied western blot evidence.
HUMAN REVIEW
The commercial owner reviews the inquiry; an applications specialist assesses target, tissue, fixation and antigen-retrieval questions before discussing suitability.
CONTEXT FOR THE NEXT TEAM
The requested application, supplied evidence and unresolved suitability gap remain explicit in all subsequent evaluation and commercial drafts.
ARIA PREPARES
Coordinate specialist review
A specialist review brief gathers relevant application evidence and open questions, with a possible evaluation outline pending specialist and customer agreement.
HUMAN REVIEW
Applications specialists review claims and evaluation recommendations; the customer’s scientific owner decides whether an evaluation fits their intended use.
CONTEXT FOR THE NEXT TEAM
If an evaluation is agreed, retain its criteria and responsibilities; otherwise preserve the evidence gap and unanswered application questions.
ARIA PREPARES
Prepare commercial follow-up
A follow-up draft reflects reviewed evidence and any customer-reported evaluation feedback, separating supported claims from open questions and possible commercial steps.
HUMAN REVIEW
The commercial owner approves follow-up after applications review; customer owners decide whether further evaluation, purchasing discussion or no action is appropriate.
CONTEXT FOR THE NEXT TEAM
Evidence limits, evaluation status and the customer’s stated next step stay attached; suitability and a purchase are never assumed.
ARIA PREPARES
Retain account context
An account note brings together the application inquiry, reviewed evidence, available evaluation feedback and customer-confirmed follow-up preferences for future conversations.
HUMAN REVIEW
The account owner reviews retained commercial context; applications specialists verify technical statements before their reuse in later customer communication.
CONTEXT FOR THE NEXT TEAM
The IHC/FFPE context and remaining uncertainties inform later inquiries; other tissues, applications or products need their own evidence review.
Technical and commercial decisions stay with the accountable specialists.
Applications specialists assess evidence and recommend evaluations. ARIA does not validate antibodies or guarantee assay performance.
- Which species and tissue, fixation time and antigen retrieval (heat-induced, citrate pH 6 or EDTA pH 9) does the lab use?
- Is there IHC-P evidence for this antibody, or another clone or format validated on FFPE?
- Which positive and negative tissue controls, and which knockout or orthogonal data, would support suitability?
- Research use only, or a clinical or diagnostic setting that changes what can be claimed?
- Does the evaluation come with a trial size, a credit, or a success criterion agreed in advance?
Other ways your team could start.
Repeat-order discussion
A customer-confirmed repeat need could prompt a commercial availability review while preserving product references and avoiding unsupported performance claims.
We build or adapt workflows on ARIA around your sources, decision criteria, reviewers and systems. Relevant outcomes connect to your other permitted workflows.
Another possible starting point: Application-to-evidence brief
Prepared work
Application-to-evidence brief
Source contextPublished
research questionScientific context
research questionScientific context
Applicability decisionRelevant science.
Suitable product?
Suitable product?
Product evidenceReview
Intended useReview
Evaluation criteriaConfirm
Research use ≠ diagnostic use
Human approvalScientific and commercial review before outreach.
Read the evidence, open questions & workflow detail
A published research question
A grant or publication can establish scientific context. It does not confirm a product need or available budget.
What the approved material supports
Review product evidence and intended use. Scientific relevance remains a hypothesis until suitability is assessed.
What remains to be understood
Clarify the application, requested evidence and evaluation criteria. Keep feedback connected to the next account conversation.
What remains unconfirmed
A grant is not discretionary reagent budget, and scientific relevance is not product suitability. Research-use-only products must not be positioned as diagnostic products.
Domain context
NIH · Funded-project records and scientific abstracts ↗FDA · Research and investigational intended-use context ↗Sources support domain context, not customer intent, deployed features or results.
Useful beyond one piece of work
Keep what the team learns.
Use confirmed application needs and engagement outcomes to refine scientific content, audience selection and future campaign messages.
How this connects to the platform and engagement
Approved business context can support additional custom workflows. Your priorities determine where you begin; relevant outcomes can inform future work.
Explore the shared ARIA platform →How discovery, deployment and expansion work →
Questions from life sciences reagent suppliers.
How are research and diagnostic intended uses kept distinct?
The application brief should carry the product’s intended use and approved evidence into scientific review. A relevant publication is not proof of suitability, and research-use-only products must not be positioned as diagnostic products.
Is this example already deployed?
This is an illustrative custom workflow, not a live product demo. Signals-to-leads and meeting insights are deployed proof areas. Your workflows, connections and approvals are defined around your business and agreed scope.
Where would our team begin?
Start with the function that needs attention: application relevance, scientific engagement, evaluation follow-up, or another agreed priority. An introductory call explores fit. After signing, Commercial Excellence discovery informs a staged plan. Existing workflows can be adapted while customer-specific workflows are developed.
Working together
What would useful work look like for your team?
These are illustrative starting points, not a fixed package. Bring your priorities; the first conversation covers business fit and relevant examples. Detailed discovery follows signing.